Great rundown on the position(s) of Merck, BMS and Roche with respect to the FDA review taking place tonight.

my interpretation (fwiw dyor) is that it will bring significant pressure onto the owners of the leading immuno oncolytic productscts to show value and improved OSR, to maintain their market standing and revenues...

a good read if you want to be familiar with the competition in the Monoclonal antibody space.

enjoy, :-)
://www.fiercepharma.com/pharma/merck-bristol-myers-roche-to-face-fda-scrutiny-for-pd-1-l1-accelerated-approvals-at-adcom-a

What are Merck, Bristol Myers and Roche planning for the big FDA cancer approval

Pharma

review? Here's our rundown

by Angus Liu |

Apr 26, 2021 3:30pm

Roche's Tecentriq, Bristol Myers Squibb's Opdivo and Merck's Keytruda will be under the microscope as the FDA convenes a multiday committee meeting to reconsider accelerated approvals granted to the cancer drugs. (FDA)

apo!



https